Stock data
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX) reported net income of US$22.37M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | US$12.52M | US$22.37M | — |
| 2024 | — | — | -US$78.78M | -US$69.68M | — |
| 2023 | — | — | -US$86.46M | -US$82.44M | — |
| 2022 | — | — | -US$92.83M | -US$91.17M | — |
| 2021 | — | — | -US$126.87M | -US$125.60M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$9.90M | — |
| 2026-03-31 | — | -US$9.04M | — |
| 2025-12-31 | — | -US$15.12M | — |
| 2025-09-30 | — | -US$8.50M | — |
| 2025-06-30 | — | -US$10.56M | — |
| 2025-03-31 | — | US$56.54M | — |
| 2024-12-31 | — | -US$15.98M | — |
| 2024-09-30 | — | -US$15.56M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.